(349) Ginsenoside-Gemcitabine Nanocomplex-based Delivery System for Enhanced Cancer Therapy
Introduction: Colorectal cancer (CRC) ranks as the third leading cause of global mortality. Despite the advancement, CRC treatment including oxaliplatin often faces limitations (1). Intravenous formulations of gemcitabine have been evaluated as a second-line CRC therapy (2,3). Herein, we developed self-assembled Ginsenoside-Gemcitabine NanoComplexes (GG-NC). We selected ginsenoside, a naturally occurring bioactive compound with anti-cancer properties, to form NC, containing gemcitabine. We demonstrated the synergistic therapeutic effect of ginsenoside and gemcitabine in colorectal cancer cell models.
Learning Objectives:
Describe the benefits of ginsenoside as a self-assembled bioactive drug delivery system
Study the potential of GG-NCs in sustained drug release, anti-cancer activity, and reducing toxicity
Analyze the advantages of naturally derived nanocomplexes in cancer therapy
